Evoke Pharma (EVOK) Competitors $2.70 +0.02 (+0.56%) Closing price 07/3/2025 01:25 PM EasternExtended Trading$2.70 0.00 (-0.18%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. MRKR, PMN, CASI, HOTH, CLRB, CGTX, LPTX, BFRG, XFOR, and GELSShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Marker Therapeutics (MRKR), Promis Neurosciences (PMN), CASI Pharmaceuticals (CASI), Hoth Therapeutics (HOTH), Cellectar Biosciences (CLRB), Cognition Therapeutics (CGTX), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), X4 Pharmaceuticals (XFOR), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors Marker Therapeutics Promis Neurosciences CASI Pharmaceuticals Hoth Therapeutics Cellectar Biosciences Cognition Therapeutics Leap Therapeutics Bullfrog AI X4 Pharmaceuticals Gelteq Evoke Pharma (NASDAQ:EVOK) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Do institutionals & insiders have more ownership in EVOK or MRKR? 22.4% of Marker Therapeutics shares are held by institutional investors. 2.3% of Evoke Pharma shares are held by insiders. Comparatively, 14.5% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, EVOK or MRKR? Evoke Pharma has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Which has preferable valuation and earnings, EVOK or MRKR? Evoke Pharma has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$10.25M0.39-$5.35M-$2.87-0.94Marker Therapeutics$6.59M2.70-$10.73M-$1.33-1.18 Does the media prefer EVOK or MRKR? In the previous week, Evoke Pharma's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score. Company Overall Sentiment Evoke Pharma Neutral Marker Therapeutics Neutral Is EVOK or MRKR more profitable? Evoke Pharma has a net margin of -43.80% compared to Marker Therapeutics' net margin of -224.46%. Marker Therapeutics' return on equity of -101.87% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-43.80% -101.91% -33.75% Marker Therapeutics -224.46%-101.87%-83.02% Do analysts prefer EVOK or MRKR? Marker Therapeutics has a consensus target price of $13.17, indicating a potential upside of 735.45%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 SummaryMarker Therapeutics beats Evoke Pharma on 10 of the 15 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.06M$3.94B$5.53B$9.04BDividend YieldN/A1.16%5.24%4.01%P/E Ratio-0.947.5127.6420.25Price / Sales0.3911.19416.59118.23Price / CashN/A6.5736.8958.07Price / Book0.572.698.035.67Net Income-$5.35M-$109.62M$3.18B$249.21M7 Day Performance2.85%3.27%2.92%3.28%1 Month Performance-21.82%6.54%3.72%5.55%1 Year Performance-58.26%32.08%35.14%21.08% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke PharmaN/A$2.71+0.6%N/A-57.9%$4.06M$10.25M-0.944Positive NewsMRKRMarker Therapeutics3.2177 of 5 stars$1.42-2.1%$13.17+827.2%-69.6%$16.41M$6.59M-1.0760Positive NewsGap UpPMNPromis Neurosciences3.3896 of 5 stars$0.47-6.0%$4.50+857.2%-71.2%$16.34MN/A-9.405Gap UpCASICASI Pharmaceuticals4.1384 of 5 stars$1.23-7.2%$4.00+225.2%-74.7%$16.30M$28.54M-0.48180Positive NewsHOTHHoth Therapeutics1.5844 of 5 stars$1.23+1.2%$4.00+226.5%+34.6%$15.98MN/A-1.074Analyst UpgradeCLRBCellectar Biosciences3.3173 of 5 stars$0.30+2.1%$12.50+4,097.4%-93.5%$15.86MN/A-0.4110Gap UpHigh Trading VolumeCGTXCognition Therapeutics2.7991 of 5 stars$0.26+1.8%$5.63+2,067.6%-74.4%$15.81MN/A-0.3520News CoverageGap UpLPTXLeap Therapeutics1.4352 of 5 stars$0.31-18.0%$4.92+1,491.2%-84.3%$15.62MN/A-0.1840High Trading VolumeBFRGBullfrog AI0.7462 of 5 stars$1.52-7.9%N/A+0.0%$15.54M$60K-1.884News CoveragePositive NewsXFORX4 Pharmaceuticals4.6684 of 5 stars$2.42-9.4%$72.33+2,889.0%-88.4%$15.46M$2.56M1.1380News CoverageHigh Trading VolumeGELSGelteqN/A$1.57-1.9%N/AN/A$15.10M$100K0.00N/ANews CoverageGap Up Related Companies and Tools Related Companies MRKR Alternatives PMN Alternatives CASI Alternatives HOTH Alternatives CLRB Alternatives CGTX Alternatives LPTX Alternatives BFRG Alternatives XFOR Alternatives GELS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
